<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490919</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3024</org_study_id>
    <nct_id>NCT00490919</nct_id>
  </id_info>
  <brief_title>Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain</brief_title>
  <official_title>Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the analgesic efficacy and safety of
      Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve
      subjects with moderate to severe chronic low back pain. The double-blind treatment
      intervention duration is 12 weeks, during which time supplemental analgesic medication
      (immediate-release oxycodone for the first 6 days post-randomization and acetaminophen or
      ibuprofen for the remainder of the double-blind phase) will be provided to all subjects in
      addition to study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical
      experience indicating it to be safe and effective in a variety of therapeutic settings for
      the relief of moderate to severe pain. BTDS is a transdermal system formulation that is
      designed to deliver a consistent and a steady dose of buprenorphine over a 7-day period with
      limited blood concentration fluctuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.</measure>
    <time_frame>Prerandomization phase consisted of a 6-10 day screening period and a &lt;27 day open-label run-in period; and a 12-week double-blind phase.</time_frame>
    <description>Pain was assessed on an 11-point numerical scale ranging from 0 = no pain to 10 = pain as bad as you can imagine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Medications Taken During Weeks 2 Through 12 of the Double-blind Phase</measure>
    <time_frame>weeks 2-12</time_frame>
    <description>Nonopioid supplemental analgesic tablets were sponsor-supplied acetaminophen or ibuprofen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</measure>
    <time_frame>Weeks 4, 8, 12 of double-blind phase</time_frame>
    <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Double-blind BTDS 10 or 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Placebo TDS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo transdermal system to match BTDS patches, applied for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal system</intervention_name>
    <description>Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days</description>
    <arm_group_label>Double-blind BTDS 10 or 20</arm_group_label>
    <other_name>Butrans™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>transdermal system (placebo) worn for 7 days</description>
    <arm_group_label>Double-blind Placebo TDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with moderate to severe chronic low back pain (lasting several hours daily)
             as their predominant pain condition for at least 3 months prior to screening,

          -  Subjects treated within the 14 days prior to screening with nonopioid therapy only, or
             with therapy including opioids at a dose of &lt;5 mg oxycodone (or equivalent) per day,

          -  Subjects whose low back pain is not adequately controlled with non-opioid analgesic
             medication and who the Investigator feels are appropriate candidates for
             around-the-clock opioid therapy

        Exclusion Criteria:

          -  Subjects who had a surgical procedure directed towards the source of back pain within
             6 months of screening or planned during the study conduct period,

          -  Subjects who are allergic to buprenorphine or who had a history of allergies to other
             opioids,

          -  Subjects who have allergies or other contraindications to transdermal delivery systems
             or patch adhesives.

        Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research; Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Care Medical Group</name>
      <address>
        <city>City of Industry</city>
        <state>California</state>
        <zip>91748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <zip>92610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates of S. FL</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Century Clinical Research, Inc.</name>
      <address>
        <city>Holly Hill</city>
        <state>Florida</state>
        <zip>32117-2257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458-7200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Flor</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Neurodiagnostic Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dawsonville</city>
        <state>Georgia</state>
        <zip>30534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Druid Oaks Health Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814-4526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Association of IN</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTT Consultants, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolby Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Clinical Research</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830-6141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sports Med Consultants, PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Morgantown</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-8311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Chicora</city>
        <state>Pennsylvania</state>
        <zip>16025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Family Care, PA</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205-1116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <results_reference>
    <citation>Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011 Dec;42(6):903-17. doi: 10.1016/j.jpainsymman.2011.04.006. Epub 2011 Sep 25.</citation>
    <PMID>21945130</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <results_first_submitted>July 15, 2010</results_first_submitted>
  <results_first_submitted_qc>August 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2010</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>opioid</keyword>
  <keyword>transdermal</keyword>
  <keyword>Moderate to severe chronic low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study dates: 27-Jun-2007 (first patient first visit) to 24-Jul-2008 (last patient last visit), at 86 medical/research sites in the USA.</recruitment_details>
      <pre_assignment_details>The open-label run-in period (N = 1024 started) was designed to select subjects for randomization in the double-blind phase who met both tolerability and responsiveness criteria for either BTDS 10 or 20 (an enriched design).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-label Run-in Period</title>
          <description>The open-label run-in period (&lt; 27 days) (N = 1024 started) was designed to select subjects for randomization who met both tolerability and responsiveness criteria for either BTDS 10 or 20 (an enriched design).
Upon completion of the run-in period, 541 subjects were randomized and received treatment in the double-blind phase. Two subjects had no safety data after the randomization visit; therefore N = 539 for the randomized safety population.</description>
        </group>
        <group group_id="P2">
          <title>Double-blind BTDS 10 or 20</title>
          <description>Buprenorphine transdermal patch (BTDS) 10 mcg/h or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase.</description>
        </group>
        <group group_id="P3">
          <title>Double-blind Placebo TDS</title>
          <description>Matching placebo transdermal patch (placebo TDS) 10 or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1024"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="541">Completed run-in and randomized; however 2 had no safety data after randomization visit (N = 539)</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Confirmed or suspected diversion</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="256">1 subject had no safety data in DB phase; therefore is excluded from randomized safety population.</participants>
                <participants group_id="P3" count="283">1 subject had no safety data in DB phase; therefore is excluded from randomized safety population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double-blind BTDS</title>
          <description>Buprenorphine transdermal patch 10 mcg/h or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
        </group>
        <group group_id="B2">
          <title>Double-blind Placebo TDS</title>
          <description>Matching placebo TDS 10 or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="256"/>
            <count group_id="B2" value="283"/>
            <count group_id="B3" value="539"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="12.50"/>
                    <measurement group_id="B2" value="50.1" spread="13.31"/>
                    <measurement group_id="B3" value="49.5" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.</title>
        <description>Pain was assessed on an 11-point numerical scale ranging from 0 = no pain to 10 = pain as bad as you can imagine.</description>
        <time_frame>Prerandomization phase consisted of a 6-10 day screening period and a &lt;27 day open-label run-in period; and a 12-week double-blind phase.</time_frame>
        <population>The full analysis population (FAP) (N = 541) [539] consisted of subjects who were randomized and received at least 1 dose of the double-blind study drug. (Two subjects did not have safety data.)</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS</title>
            <description>Buprenorphine transdermal patch 10 mcg/h or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo TDS</title>
            <description>Matching placebo TDS 10 or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.</title>
          <description>Pain was assessed on an 11-point numerical scale ranging from 0 = no pain to 10 = pain as bad as you can imagine.</description>
          <population>The full analysis population (FAP) (N = 541) [539] consisted of subjects who were randomized and received at least 1 dose of the double-blind study drug. (Two subjects did not have safety data.)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="1.263"/>
                    <measurement group_id="O2" value="7.17" spread="1.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="1.283"/>
                    <measurement group_id="O2" value="2.56" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Primary outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="2.738"/>
                    <measurement group_id="O2" value="4.38" spread="2.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing average pain over the last 24 hours scores after treatment discontinuation were imputed using BOCF for adverse event-related withdrawals and LOCF for withdrawals due to other reasons.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0104</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects general linear model with repeated measures.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
            <estimate_desc>Double-blind analysis (comparison between BTDS and placebo TDS) at week 12 of the double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Medications Taken During Weeks 2 Through 12 of the Double-blind Phase</title>
        <description>Nonopioid supplemental analgesic tablets were sponsor-supplied acetaminophen or ibuprofen.</description>
        <time_frame>weeks 2-12</time_frame>
        <population>Subjects in the full analysis population who took at least one dose of supplemental analgesic medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS</title>
            <description>Buprenorphine transdermal patch 10 mcg/h or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo TDS</title>
            <description>Matching placebo TDS 10 or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Medications Taken During Weeks 2 Through 12 of the Double-blind Phase</title>
          <description>Nonopioid supplemental analgesic tablets were sponsor-supplied acetaminophen or ibuprofen.</description>
          <population>Subjects in the full analysis population who took at least one dose of supplemental analgesic medication.</population>
          <units>tablets</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.620" spread="0.0658"/>
                    <measurement group_id="O2" value="0.743" spread="0.0574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1586</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holms methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0874</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.296</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
            <estimate_desc>Mean comparison from weeks 2-12 of the double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</title>
        <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
        <time_frame>Weeks 4, 8, 12 of double-blind phase</time_frame>
        <population>The full analysis population (FAP) (N = 541) consisted of subjects who were randomized and received at least 1 dose of the double-blind study drug. 2 subjects did not have safety data (N = 539).</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS</title>
            <description>Buprenorphine transdermal patch 10 mcg/h or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo TDS</title>
            <description>Matching placebo TDS 10 or 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
          </group>
        </group_list>
        <measure>
          <title>The Sleep Disturbance Subscale in the Medical Outcome Study (MOS) Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</title>
          <description>The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
          <population>The full analysis population (FAP) (N = 541) consisted of subjects who were randomized and received at least 1 dose of the double-blind study drug. 2 subjects did not have safety data (N = 539).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.84" spread="25.552"/>
                    <measurement group_id="O2" value="41.20" spread="26.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.63" spread="26.276"/>
                    <measurement group_id="O2" value="39.87" spread="26.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.97" spread="26.871"/>
                    <measurement group_id="O2" value="40.42" spread="26.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary comparison between groups was based on estimates and contrasts for the weeks 4, 8, and 12 mean values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0062</p_value>
            <p_value_desc>To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holms methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects general linear model with repeated measures.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.605</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.55</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
            <estimate_desc>Treatment comparison over Weeks 4, 8, and 12.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) that occurred after the signing of the informed consent up to end of study and 7 days after, discontinuation, or Serious AEs occurring up to 30 days following the last study visit were followed until the AE resolved or stabilized.</time_frame>
      <desc>AEs were obtained through spontaneous reports, subject interview, and subject diaries.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind BTDS 10, 20</title>
          <description>Buprenorphine transdermal patch 10 mcg/h or 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="E2">
          <title>Double-blind Placebo TDS 10, 20</title>
          <description>Matching placebo TDS 10 or 20 applied for 7-day wear</description>
        </group>
        <group group_id="E3">
          <title>Open-label Run-in Period, BTDS 5, 10, 20</title>
          <description>Open-label BTDS 5, 10, 20 applied for 7-day wear</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Homicidal thoughts</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug abuser</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="437" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="240" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1024"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systematic and nonsystematic assessments were used.</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="1024"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader, Medical Director</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

